You are here
Anti-Tumor Activity of Talabostat, Gemcitabine Combination To Be Determined in Phase 2 Trial
The trial design is a single-arm, two-stage study in up to 60 patients with metastatic pancreatic cancer. The primary clinical endpoint will be six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status.
"We are very pleased to have initiated our fifth Phase 2 talabostat study," said Don Kiepert, President and CEO of Point Therapeutics. "Our preclinical work with talabostat in combination with gemcitabine demonstrated encouraging results. Overall tumor rejection rates in mice increased to 45% when treated with the talabostat/gemcitabine combination as opposed to a 23% rejection with gemcitabine alone. We are hopeful that these results will translate into the clinical setting given the lack of options for patients facing pancreatic cancer."
According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2005 alone, 32,180 new cases of pancreatic cancer will be diagnosed and 31,800 people will die of the disease.
Source: Point Therapeutics, Inc.